Cargando…

SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis

INTRODUCTION: Pheochromocytomas and paragangliomas (PCC/PGL) are rare neuroendocrine tumors and can secrete catecholamine. Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Tingwei, Yang, Yifan, Jiang, Lei, Xie, Jing, Zhong, Xu, Wu, Luming, Jiang, Yiran, Zhang, Cui, Zhou, Weiwei, Ye, Lei, Ning, Guang, Wang, Weiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061060/
https://www.ncbi.nlm.nih.gov/pubmed/37008946
http://dx.doi.org/10.3389/fendo.2023.1121397
_version_ 1785017215811059712
author Su, Tingwei
Yang, Yifan
Jiang, Lei
Xie, Jing
Zhong, Xu
Wu, Luming
Jiang, Yiran
Zhang, Cui
Zhou, Weiwei
Ye, Lei
Ning, Guang
Wang, Weiqing
author_facet Su, Tingwei
Yang, Yifan
Jiang, Lei
Xie, Jing
Zhong, Xu
Wu, Luming
Jiang, Yiran
Zhang, Cui
Zhou, Weiwei
Ye, Lei
Ning, Guang
Wang, Weiqing
author_sort Su, Tingwei
collection PubMed
description INTRODUCTION: Pheochromocytomas and paragangliomas (PCC/PGL) are rare neuroendocrine tumors and can secrete catecholamine. Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and metastasis. This study aimed to clarify the potential effect of SDHB IHC as a predictive marker for tumor progression in PCC/PGL patients. METHODS: We included PCC/PGL patients diagnosed in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from 2002 to 2014 for retrospective analysis and discovered that SDHB (-) staining patients had poorer prognoses. Then we examined SDHB protein expression by IHC on all tumors in the prospective series, which was composed of patients from 2015 to 2020 in our center. RESULTS: In the retrospective series, the median follow-up was 167 months, and during follow-up, 14.4% (38/264) patients developed metastasis or recurrence, and 8.0% (22/274) patients died. Retrospective analysis revealed that 66.7% (6/9) of participants in the SDHB (-) group and 15.7% (40/255) of those in the SDHB (+) group developed progressive tumors (OR: 10.75, 95% CI: 2.72-52.60, P=0.001), and SDHB (-) was independently associated with poor outcomes after adjusting by other clinicopathological parameters (OR: 11.68, 95% CI: 2.58-64.45, P=0.002). SDHB (-) patients had shorter disease-free survival (DFS) and overall survival (OS) (P<0.001) and SDHB (-) was significantly associated with shorter median DFS (HR: 6.89, 95% CI: 2.41-19.70, P<0.001) in multivariate cox proportional hazard analysis. In the prospective series, the median follow-up was 28 months, 4.7% (10/213) patients developed metastasis or recurrence, and 0.5% (1/217) patient died. For the prospective analysis, 18.8% (3/16) of participants in the SDHB (-) group had progressive tumors compared with 3.6% (7/197) in the SDHB (+) group (RR: 5.28, 95% CI: 1.51-18.47, P=0.009), statistical significance remained (RR: 3.35, 95% CI: 1.20-9.38, P=0.021) after adjusting for other clinicopathological factors. CONCLUSIONS: Our findings demonstrated patients with SDHB (-) tumors had a higher possibility of poor outcomes, and SDHB IHC can be regarded as an independent biomarker of prognosis in PCC/PGL.
format Online
Article
Text
id pubmed-10061060
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100610602023-03-31 SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis Su, Tingwei Yang, Yifan Jiang, Lei Xie, Jing Zhong, Xu Wu, Luming Jiang, Yiran Zhang, Cui Zhou, Weiwei Ye, Lei Ning, Guang Wang, Weiqing Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Pheochromocytomas and paragangliomas (PCC/PGL) are rare neuroendocrine tumors and can secrete catecholamine. Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and metastasis. This study aimed to clarify the potential effect of SDHB IHC as a predictive marker for tumor progression in PCC/PGL patients. METHODS: We included PCC/PGL patients diagnosed in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from 2002 to 2014 for retrospective analysis and discovered that SDHB (-) staining patients had poorer prognoses. Then we examined SDHB protein expression by IHC on all tumors in the prospective series, which was composed of patients from 2015 to 2020 in our center. RESULTS: In the retrospective series, the median follow-up was 167 months, and during follow-up, 14.4% (38/264) patients developed metastasis or recurrence, and 8.0% (22/274) patients died. Retrospective analysis revealed that 66.7% (6/9) of participants in the SDHB (-) group and 15.7% (40/255) of those in the SDHB (+) group developed progressive tumors (OR: 10.75, 95% CI: 2.72-52.60, P=0.001), and SDHB (-) was independently associated with poor outcomes after adjusting by other clinicopathological parameters (OR: 11.68, 95% CI: 2.58-64.45, P=0.002). SDHB (-) patients had shorter disease-free survival (DFS) and overall survival (OS) (P<0.001) and SDHB (-) was significantly associated with shorter median DFS (HR: 6.89, 95% CI: 2.41-19.70, P<0.001) in multivariate cox proportional hazard analysis. In the prospective series, the median follow-up was 28 months, 4.7% (10/213) patients developed metastasis or recurrence, and 0.5% (1/217) patient died. For the prospective analysis, 18.8% (3/16) of participants in the SDHB (-) group had progressive tumors compared with 3.6% (7/197) in the SDHB (+) group (RR: 5.28, 95% CI: 1.51-18.47, P=0.009), statistical significance remained (RR: 3.35, 95% CI: 1.20-9.38, P=0.021) after adjusting for other clinicopathological factors. CONCLUSIONS: Our findings demonstrated patients with SDHB (-) tumors had a higher possibility of poor outcomes, and SDHB IHC can be regarded as an independent biomarker of prognosis in PCC/PGL. Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10061060/ /pubmed/37008946 http://dx.doi.org/10.3389/fendo.2023.1121397 Text en Copyright © 2023 Su, Yang, Jiang, Xie, Zhong, Wu, Jiang, Zhang, Zhou, Ye, Ning and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Su, Tingwei
Yang, Yifan
Jiang, Lei
Xie, Jing
Zhong, Xu
Wu, Luming
Jiang, Yiran
Zhang, Cui
Zhou, Weiwei
Ye, Lei
Ning, Guang
Wang, Weiqing
SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
title SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
title_full SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
title_fullStr SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
title_full_unstemmed SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
title_short SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
title_sort sdhb immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: a retrospective and prospective analysis
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061060/
https://www.ncbi.nlm.nih.gov/pubmed/37008946
http://dx.doi.org/10.3389/fendo.2023.1121397
work_keys_str_mv AT sutingwei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT yangyifan sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT jianglei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT xiejing sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT zhongxu sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT wuluming sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT jiangyiran sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT zhangcui sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT zhouweiwei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT yelei sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT ningguang sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis
AT wangweiqing sdhbimmunohistochemistryforprognosisofpheochromocytomaandparagangliomaaretrospectiveandprospectiveanalysis